62903-14-4

Basic information

• Product Name: 4-(3-CHLOROPHENYL)-4-OXOBUTYRIC ACID
• Synonyms: 4-(3-CHLOROPHENYL)-4-OXOBUTYRIC ACID
• CAS NO: 62903-14-4
• Molecular Formula: C₁₀H₉ClO₃
• Molecular Weight: 212.63
• Mol File: 62903-14-4.mol

Chemical Properties

• Melting Point: 93-101°C
• Boiling Point: 406.7°C at 760 mmHg
• Flash Point: 199.8°C
• Appearance: /
• Density: 1.324g/cm³
• Vapor Pressure: 2.41E-07mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: 2-8°C
• PKA: 4.44±0.17(Predicted)
• CAS DataBase Reference: 4-(3-CHLOROPHENYL)-4-OXOBUTYRIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-CHLOROPHENYL)-4-OXOBUTYRIC ACID(62903-14-4)
• EPA Substance Registry System: 4-(3-CHLOROPHENYL)-4-OXOBUTYRIC ACID(62903-14-4)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 62903-14-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(3-chlorophenyl)-4-oxobutyric acid is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a building block for the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(3-chlorophenyl)-4-oxobutyric acid is utilized as a key component in the production of pesticides and other agrochemical products. Its chemical properties make it suitable for creating effective and targeted solutions for agricultural applications.
Used in Organic Synthesis:
As a versatile intermediate, 4-(3-chlorophenyl)-4-oxobutyric acid is employed in organic synthesis for the creation of a wide range of compounds. Its structural features facilitate its use in the development of new chemical entities with potential applications in various industries.

InChI:InChI=1/C10H9ClO3/c11-8-3-1-2-7(6-8)9(12)4-5-10(13)14/h1-3,6H,4-5H2,(H,13,14)

Upstream product

• 108-30-5 succinic acid anhydride 
• 36229-42-2 (3-chlorophenyl)magnesium bromide 
• 108-90-7 chlorobenzene 
• 99-02-5 3'-Chloroacetophenone 
• 34555-37-8 3-(3-chlorobenzoyl)propionitrile 
• 2905-65-9 methyl 3-chlorobenzoate 
• 106-65-0 Dimethyl succinate 

Downstream Products

• 1328082-39-8 C₁₆H₁₄ClNO₂ 
• 1428426-19-0 C₁₀H₈ClNO₅ 
• 1417520-48-9 C₁₁H₁₀ClNO₅ 
• 80452-54-6 methyl 4-(2-amino-5-chlorophenyl)-4-oxobutyrate 
• 1417520-49-0 C₁₉H₁₇ClN₂O₆ 
• 1417520-50-3 C₁₉H₁₉ClN₂O₄ 
• 1417520-51-4 C₂₇H₂₅ClN₂O₅ 
• 1346599-56-1 DM-4103 
• 1346599-75-4 DM-4107 
• 1270301-96-6 (+)-(S)-γ-(3-chlorophenyl)-γ-butyrolactone 

Relevant articles and documents

A sertraline hydrochloride impurity preparation method (by machine translation)

The invention discloses a sertraline hydrochloride preparation method of impurities, in particular comprising a formula 6 by the Leuckart reaction to obtain a compound of the formula 7 compound, with the insulated hydrochloride salt obtained in the reaction formula 8 cis-isomer of the compound, wherein the formula 6 compound in the location of the chloropropyl substituted cyclohexanone substituted meta or para position. Preparation method of this invention is simple, high purity, obtained impurity can be used for qualitative and quantitative analysis, so as to improve the safety of medicine sertraline hydrochloride. (by machine translation)

NOVEL PYRIDAZONES AND TRIAZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the general formula wherein R1, R2, R3, X and a are as described in the description and in the claims, as well as or pharmaceutically acceptable salts thereof. The invention also contains compositions including the compounds and methods of using the compounds.

Highly enantioselective [3+2] coupling of cyclic enamides with quinone monoimines promoted by a chiral phosphoric acid

Enantioselective [3+2] coupling of cyclic enamides with quinone monoimines was realised using a chiral phosphoric acid as a catalyst. This transformation allowed for the synthesis of highly enantioenriched polycyclic 2,3-dihydrobenzofurans (up to 99.9% ee). The absolute configuration of one product was determined by an X-ray crystal structural analysis. We also found a possible mechanism for this reaction.

Design, synthesis and antihypertensive screening of novel pyridazine substituted s-triazin-2-imine/one/thione derivatives

Some new 7-substituted-phenyl-3,4,8,9-tetrahydro-2H-pyridazino[1,6-a][1,3, 5]triazin-2-imine/one/thione derivatives were synthesized by a sequence of reactions starting from appropriate aryl hydrocarbons. The final compounds were screened for antihypertensive activities by non-invasive method using Tail Cuff method. All the test compounds showed significant antihypertensive activity; 7-(biphenyl-4-yl)-3,4,8,9-tetrahydro-2H-pyridazino[1,6-a][1,3,5]triazin-2-imine (4p) exhibited antihypertensive activity more than the reference standard drugs.

Synthesis of the major metabolites of Tolvaptan

Tolvaptan is a nonpeptide arginine vasopressin (AVP) V2-receptor antagonist and used in the treatment of heart failure, cirrhosis, syndrome of inappropriate antidiuretic hormone secretion or other high-volume capacity of hyponatremia. The metab

4-phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity

4-phenyl-4-oxo-butanoic acid derivatives for use in the treatment of the human or animal body by therepy; particularly as kynurenine-3-hydroxylase inhibitors, in the prevention and/or treatment of a neurodegenerative disease wherein the inhibition of such an enyzme is needed. The present invention further comprises a selected class of the above mentioned 4-phenyl-4-oxo-butanoic acid derivatives, their pharmaceutically acceptable salts, a process for their preparation and pharmaceutical compositions containing them.

Dihydropyridazinones, pyridazinones and related compounds as fungicides

This invention relates to substituted dihydropyridazinones, pyridazinones and related compounds, of the formula STR1 wherein A, Q, D and R1 are as defined within, compositions containing these compounds and methods of controlling agricultural and mammalian fungal diseases.

SUBSTITUTED THIO-SUBSTITUTED BENZYL-PROPIONYL-L-PROLINES

This disclosure describes novel substituted ω-aroyl(propionyl or butyryl)-L-prolines and the esters and cationic salts thereof which are useful as hypotensive agents in mammals.

6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents

This disclosure describes novel substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines useful as hypotensive agents.